Medical device firm ControlRad has secured $15 million in funding to further its efforts to bring its Trace radiation dose-reduction technology for fluoroscopy to market.
The funding was led by Questa Capital of San Francisco.
The U.S. Food and Drug Administration (FDA) cleared Trace for market in May. It reduces radiation exposure by up to 89%, according to the firm.
